- Leap Therapeutics (LPTX, Financial) will host a virtual KOL event on April 23, 2025, at 2:30 p.m. ET, focused on their lead drug candidate, sirexatamab (DKN-01).
- The event will discuss positive data from the Phase 2 DeFianCe study, targeting advanced microsatellite stable colorectal cancer.
- Dr. Zev A. Wainberg and Dr. Cynthia Sirard will lead the discussion, followed by a live Q&A session.
Leap Therapeutics, Inc. (LPTX), a biotechnology company specializing in targeted and immuno-oncology therapeutics, announced a virtual Key Opinion Leader (KOL) event scheduled for April 23, 2025, at 2:30 p.m. ET. The event will focus on the company’s lead drug candidate, sirexatamab (DKN-01), which is being studied for its effectiveness in treating second-line patients with advanced microsatellite stable (MSS) colorectal cancer.
The event will feature Dr. Zev A. Wainberg, Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program, alongside Leap's Chief Medical Officer, Dr. Cynthia Sirard. They will discuss the unmet needs in colorectal cancer treatment and review positive data from Part B of the Phase 2 DeFianCe study of sirexatamab, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein.
A live Q&A session will follow the presentation, and a replay will be available on Leap Therapeutics’ investor relations website for those unable to attend the live event. Interested parties can access further information and register for the event via Leap's official channels.
Leap Therapeutics (LPTX, Financial) continues to advance its pipeline, including sirexatamab, which is their most advanced clinical program targeting colorectal cancer. Investors and interested parties can find more details on the company’s website and review their public filings available through the SEC.